MedTrace Logo

The Safety and Tolerability of Pirfenidone for BOS After HCT

NCT03315741 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-06-13

No results posted yet for this study

Summary

This is a phase 1, non-randomized, single-arm, open label, single center clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopoietic cell transplant.

Conditions

  • Bronchiolitis Obliterans
  • Graft Vs Host Disease

Interventions

DRUG

Pirfenidone 267 MG [Esbriet]

Tolerability of drug

Sponsors & Collaborators

Principal Investigators

  • Joe L Hsu, MD, MPH · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2022-02-27
Completion
2022-04-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03315741 on ClinicalTrials.gov